| Towards tuberculosis elimination: an action framework for low-incidence countries K Lönnroth, GB Migliori, I Abubakar, L D'Ambrosio, G De Vries, R Diel, ... European Respiratory Journal 45 (4), 928-952, 2015 | 871 | 2015 |
| Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis R Diel, D Goletti, G Ferrara, G Bothamley, D Cirillo, B Kampmann, ... European Respiratory Journal 37 (1), 88-99, 2011 | 764 | 2011 |
| A framework for malaria elimination World Health Organization World Health Organization, 2017 | 360 | 2017 |
| Latent Tuberculosis in HIV positive, diagnosed by the M. Tuberculosis Specific Interferon-γ test I Brock, M Ruhwald, B Lundgren, H Westh, LR Mathiesen, P Ravn Respiratory research 7, 1-9, 2006 | 333 | 2006 |
| A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human JT van Dissel, SA Joosten, ST Hoff, D Soonawala, C Prins, DA Hokey, ... Vaccine 32 (52), 7098-7107, 2014 | 267 | 2014 |
| Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis M Ruhwald, T Bodmer, C Maier, M Jepsen, MB Haaland, J Eugen-Olsen, ... European respiratory journal 32 (6), 1607-1615, 2008 | 245 | 2008 |
| Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis NN Chegou, J Heyckendorf, G Walzl, C Lange, M Ruhwald European Respiratory Journal 43 (5), 1472-1486, 2014 | 200 | 2014 |
| Point‐of‐care diagnosis of tuberculosis: Past, present and future K Dheda, M Ruhwald, G Theron, J Peter, WC Yam Respirology 18 (2), 217-232, 2013 | 184 | 2013 |
| IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions M Ruhwald, MG Aabye, P Ravn Expert review of molecular diagnostics 12 (2), 175-187, 2012 | 184 | 2012 |
| Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo … S Abraham, HB Juel, P Bang, HM Cheeseman, RB Dohn, T Cole, ... The Lancet infectious diseases 19 (10), 1091-1100, 2019 | 176 | 2019 |
| Antigen availability shapes T cell differentiation and function during tuberculosis AO Moguche, M Musvosvi, A Penn-Nicholson, CR Plumlee, H Mearns, ... Cell host & microbe 21 (6), 695-706. e5, 2017 | 174 | 2017 |
| CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7. 7 M Ruhwald, M Bjerregaard-Andersen, P Rabna, K Kofoed, J Eugen-Olsen, ... Microbes and infection 9 (7), 806-812, 2007 | 167 | 2007 |
| Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent … E Bélard, S Semb, M Ruhwald, AM Werlinrud, B Soborg, FK Jensen, ... Inflammatory bowel diseases 17 (11), 2340-2349, 2011 | 165 | 2011 |
| A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis M Ruhwald, J Dominguez, I Latorre, M Losi, L Richeldi, MB Pasticci, ... Tuberculosis 91 (3), 260-267, 2011 | 152 | 2011 |
| IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay M Ruhwald, M Bjerregaard-Andersen, P Rabna, J Eugen-Olsen, P Ravn BMC research notes 2, 1-6, 2009 | 148 | 2009 |
| Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection E Nemes, V Rozot, H Geldenhuys, N Bilek, S Mabwe, D Abrahams, ... American journal of respiratory and critical care medicine 196 (5), 638-648, 2017 | 147 | 2017 |
| Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10 M Ruhwald, J Petersen, K Kofoed, H Nakaoka, LE Cuevas, L Lawson, ... PloS one 3 (8), e2858, 2008 | 144 | 2008 |
| Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3 … M Ruhwald, H Aggerbeck, RV Gallardo, ST Hoff, JI Villate, B Borregaard, ... The Lancet Respiratory Medicine 5 (4), 259-268, 2017 | 127 | 2017 |
| Correlates for disease progression and prognosis during concurrent HIV/TB infection JFD Siawaya, M Ruhwald, J Eugen-Olsen, G Walzl International journal of infectious diseases 11 (4), 289-299, 2007 | 98 | 2007 |
| Dose optimization of H56: IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial S Suliman, AKK Luabeya, H Geldenhuys, M Tameris, ST Hoff, Z Shi, ... American journal of respiratory and critical care medicine 199 (2), 220-231, 2019 | 96 | 2019 |
